{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:19:24Z","timestamp":1786979964095,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,5,24]],"date-time":"2020-05-24T00:00:00Z","timestamp":1590278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,24]],"date-time":"2020-05-24T00:00:00Z","timestamp":1590278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The objective of this study was to compare rheumatoid arthritis (RA) disease activity and patient-reported outcomes (PROs) in a national sample of patients with RA with\/without Sj\u00f6gren\u2019s syndrome (SS). Adults with RA from a large observational US registry (Corrona RA) with known SS status between 22 April 2010 and 31 July 2018 and a visit 12 (\u00b1\u20093) months after index date were identified (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200936,256\/52,757). SS status: determined from a yes\/no variable reported at enrolment into the Corrona RA registry and follow-up visits. Index date: date that SS status was recorded (yes\/no). Patients received biologic or targeted synthetic disease-modifying antirheumatic drugs as part of standard care. Patients with RA only were followed for\u2009\u2265\u200912\u00a0months to confirm the absence of SS. Patients were frequency- and propensity-score matched (PSM) 1:1 and stratified by disease duration and treatment response-associated variables, respectively. Clinical Disease Activity Index (CDAI) and PROs 12\u00a0months after index visit were compared in patients with and without SS. Baseline characteristics in 283 pairs of PSM patients were balanced. Mean change in CDAI score was numerically lower in patients with RA and SS than patients with RA only (8.8 vs 9.3). Reductions in PROs of pain, fatigue and stiffness were two- to threefold lower for patients with RA and SS versus RA only. Reductions in RA disease activity and RA-related PROs were lower in patients with RA and SS versus those with RA only. Our data indicate that SS adds to treatment challenges; physicians may wish to consider SS status when managing patients with RA.\n                  <\/jats:p>","DOI":"10.1007\/s00296-020-04602-8","type":"journal-article","created":{"date-parts":[[2020,5,24]],"date-time":"2020-05-24T01:02:37Z","timestamp":1590282157000},"page":"1239-1248","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Disease activity and patient-reported outcomes in patients with rheumatoid arthritis and Sj\u00f6gren\u2019s syndrome enrolled in a large observational US registry"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0170-2747","authenticated-orcid":false,"given":"Leslie R.","family":"Harrold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0201-4030","authenticated-orcid":false,"given":"Sabrina","family":"Rebello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean E.","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evo","family":"Alemao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6674-9901","authenticated-orcid":false,"given":"Joel M.","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7681-4615","authenticated-orcid":false,"given":"Elliot D.","family":"Rosenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,24]]},"reference":[{"key":"4602_CR1","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2147\/CLEP.S47399","volume":"6","author":"R Patel","year":"2014","unstructured":"Patel R, Shahane A (2014) The epidemiology of Sjogren's syndrome. Clin Epidemiol 6:247\u2013255. https:\/\/doi.org\/10.2147\/CLEP.S47399","journal-title":"Clin Epidemiol"},{"key":"4602_CR2","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3899\/jrheum.180392","volume":"46","author":"CP Mavragani","year":"2019","unstructured":"Mavragani CP, Moutsopoulos HM (2019) Primary versus secondary Sjogren syndrome: is it time to reconsider these terms? J Rheumatol 46:665\u2013666. https:\/\/doi.org\/10.3899\/jrheum.180392","journal-title":"J Rheumatol"},{"key":"4602_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.39480","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SL et al (2016) 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res 68:1\u201326. https:\/\/doi.org\/10.1002\/art.39480","journal-title":"Arthritis Care Res"},{"key":"4602_CR4","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landew\u00e9 R, Bijlsma J et al (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76:960\u2013977. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210715","journal-title":"Ann Rheum Dis"},{"key":"4602_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1136\/annrheumdis-2016-210571","volume":"76","author":"CH Shiboski","year":"2017","unstructured":"Shiboski CH, Shiboski SC, Seror R et al (2017) 2016 American College of Rheumatology\/European League Against Rheumatism classification criteria for primary Sjogren's syndrome: a consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis 76:9\u201316. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210571","journal-title":"Ann Rheum Dis"},{"key":"4602_CR6","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1093\/rheumatology\/keu400","volume":"54","author":"LE Brown","year":"2015","unstructured":"Brown LE, Frits ML, Iannaccone CK et al (2015) Clinical characteristics of RA patients with secondary SS and association with joint damage. Rheumatology (Oxford) 54:816\u2013820. https:\/\/doi.org\/10.1093\/rheumatology\/keu400","journal-title":"Rheumatology (Oxford)"},{"key":"4602_CR7","unstructured":"Alemao E, Saini, Y, Bao, Y et al (2018) Do anti-citrullinated protein antibodies and anti-Sj\u00f6gren\u2019s-syndrome-related antigen a double positive patients with secondary Sj\u00f6gren\u2019s syndrome and RA have higher joint disease activity? [abstract]. Arthritis Rheumatol 70(suppl 10):abstract 1463"},{"key":"4602_CR8","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1167\/iovs.03-0915","volume":"46","author":"P Mertzanis","year":"2005","unstructured":"Mertzanis P, Abetz L, Rajagopalan K et al (2005) The relative burden of dry eye in patients' lives: comparisons to a U.S. normative sample. Investig Ophthalmol Vis Sci 46:46\u201350. https:\/\/doi.org\/10.1167\/iovs.03-0915","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"4602_CR9","unstructured":"Alemao E, Saini, Y, Bao Y et al (2018) The joint disease burden in patients with secondary Sj\u00f6gren\u2019s syndrome and RA compared to patients with RA only [abstract]. Arthritis Rheumatol 70(suppl 10):abstract 2506"},{"key":"4602_CR10","volume-title":"SF-36 health survey: manual and interpretation guide","author":"JE Ware","year":"1993","unstructured":"Ware JE, Snow KK, Kosinski M et al (1993) SF-36 health survey: manual and interpretation guide. The Health Institute, New England Medical Center, Boston"},{"key":"4602_CR11","doi-asserted-by":"publisher","first-page":"e000066","DOI":"10.1136\/rmdopen-2015-000066","volume":"1","author":"J Payet","year":"2015","unstructured":"Payet J, Belkhir R, Gottenberg JE et al (2015) ACPA-positive primary Sjogren's syndrome: true primary or rheumatoid arthritis-associated Sjogren's syndrome? RMD Open 1:e000066. https:\/\/doi.org\/10.1136\/rmdopen-2015-000066","journal-title":"RMD Open"},{"key":"4602_CR12","doi-asserted-by":"publisher","first-page":"390","DOI":"10.5114\/ceji.2017.72807","volume":"42","author":"W Kurowska","year":"2017","unstructured":"Kurowska W, Kuca-Warnawin EH, Radzikowska A et al (2017) The role of anti-citrullinated protein antibodies (ACPA) in the pathogenesis of rheumatoid arthritis. Cent Eur J Immunol 42:390\u2013398. https:\/\/doi.org\/10.5114\/ceji.2017.72807","journal-title":"Cent Eur J Immunol"},{"key":"4602_CR13","doi-asserted-by":"publisher","first-page":"R949","DOI":"10.1186\/ar1767","volume":"7","author":"AHM van der Helm-van Mil","year":"2005","unstructured":"van der Helm-van Mil AHM, Verpoort KN, Breedveld FC et al (2005) Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther 7:R949\u2013958. https:\/\/doi.org\/10.1186\/ar1767","journal-title":"Arthritis Res Ther"},{"key":"4602_CR14","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s10067-007-0800-1","volume":"27","author":"I Alexiou","year":"2008","unstructured":"Alexiou I, Germenis A, Koutroumpas A et al (2008) Anti-cyclic citrullinated peptide-2 (CCP2) autoantibodies and extra-articular manifestations in Greek patients with rheumatoid arthritis. Clin Rheumatol 27:511\u2013513. https:\/\/doi.org\/10.1007\/s10067-007-0800-1","journal-title":"Clin Rheumatol"},{"key":"4602_CR15","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1093\/rheumatology\/kes374","volume":"52","author":"J He","year":"2013","unstructured":"He J, Ding Y, Feng M et al (2013) Characteristics of Sjogren's syndrome in rheumatoid arthritis. Rheumatology (Oxford) 52:1084\u20131089. https:\/\/doi.org\/10.1093\/rheumatology\/kes374","journal-title":"Rheumatology (Oxford)"},{"key":"4602_CR16","first-page":"S96","volume":"34","author":"JM Kremer","year":"2016","unstructured":"Kremer JM (2016) The Corrona US registry of rheumatic and autoimmune diseases. Clin Exp Rheumatol 34:S96\u2013S99","journal-title":"Clin Exp Rheumatol"},{"key":"4602_CR17","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC (2011) An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 46:399\u2013424. https:\/\/doi.org\/10.1080\/00273171.2011.568786","journal-title":"Multivariate Behav Res"},{"key":"4602_CR18","first-page":"S100","volume":"23","author":"D Aletaha","year":"2005","unstructured":"Aletaha D, Smolen J (2005) The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 23:S100\u2013108","journal-title":"Clin Exp Rheumatol"},{"key":"4602_CR19","doi-asserted-by":"publisher","first-page":"830","DOI":"10.5114\/aoms.2017.70300","volume":"14","author":"A Omma","year":"2018","unstructured":"Omma A, Tecer D, Kucuksahin O et al (2018) Do the European League Against Rheumatism (EULAR) Sjogren's syndrome outcome measures correlate with impaired quality of life, fatigue, anxiety and depression in primary Sjogren's syndrome? Arch Med Sci 14:830\u2013837. https:\/\/doi.org\/10.5114\/aoms.2017.70300","journal-title":"Arch Med Sci"},{"key":"4602_CR20","first-page":"721","volume":"35","author":"F Ferro","year":"2017","unstructured":"Ferro F, Elefante E, Luciano N et al (2017) One year in review 2017: novelties in the treatment of rheumatoid arthritis. Clin Exp Rheumatol 35:721\u2013734","journal-title":"Clin Exp Rheumatol"},{"key":"4602_CR21","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1136\/ard.58.7.415","volume":"58","author":"T Uhlig","year":"1999","unstructured":"Uhlig T, Kvien TK, Jensen JL et al (1999) Sicca symptoms, saliva and tear production, and disease variables in 636 patients with rheumatoid arthritis. Ann Rheum Dis 58:415\u2013422. https:\/\/doi.org\/10.1136\/ard.58.7.415","journal-title":"Ann Rheum Dis"},{"key":"4602_CR22","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1590\/S0104-42302011000300015","volume":"57","author":"DC Antero","year":"2011","unstructured":"Antero DC, Parra AG, Miyazaki FH et al (2011) Secondary Sjogren's syndrome and disease activity of rheumatoid arthritis. Rev Assoc Med Bras 57:319\u2013322","journal-title":"Rev Assoc Med Bras"},{"key":"4602_CR23","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/j.1756-185X.2012.01717.x","volume":"15","author":"HJ Haga","year":"2012","unstructured":"Haga HJ, Naderi Y, Moreno AM et al (2012) A study of the prevalence of sicca symptoms and secondary Sjogren's syndrome in patients with rheumatoid arthritis, and its association to disease activity and treatment profile. Int J Rheum Dis 15:284\u2013288. https:\/\/doi.org\/10.1111\/j.1756-185X.2012.01717.x","journal-title":"Int J Rheum Dis"},{"key":"4602_CR24","doi-asserted-by":"publisher","first-page":"e0172056","DOI":"10.1371\/journal.pone.0172056","volume":"12","author":"A Lackner","year":"2017","unstructured":"Lackner A, Ficjan A, Stradner MH et al (2017) It's more than dryness and fatigue: the patient perspective on health-related quality of life in Primary Sjogren's Syndrome\u2014a qualitative study. PLoS ONE 12:e0172056. https:\/\/doi.org\/10.1371\/journal.pone.0172056","journal-title":"PLoS ONE"},{"issue":"Suppl 107","key":"4602_CR25","first-page":"94","volume":"35","author":"DF McWilliams","year":"2017","unstructured":"McWilliams DF, Walsh DA (2017) Pain mechanisms in rheumatoid arthritis. Clin Exp Rheumatol 35(Suppl 107):94\u2013101","journal-title":"Clin Exp Rheumatol"},{"key":"4602_CR26","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.oooo.2015.02.479","volume":"119","author":"HF Oliveira","year":"2015","unstructured":"Oliveira HF, de Souza TR, Carvalho CN et al (2015) Serologic profile and clinical markers of Sjogren syndrome in patients with rheumatoid arthritis. Oral Surg Oral Med Oral Pathol Oral Radiol 119:628\u2013635. https:\/\/doi.org\/10.1016\/j.oooo.2015.02.479","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"4602_CR27","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jtos.2016.09.005","volume":"15","author":"SV Aluru","year":"2017","unstructured":"Aluru SV, Shweta A, Bhaskar S et al (2017) Tear fluid protein changes in dry eye syndrome associated with rheumatoid arthritis: a proteomic approach. Ocul Surf 15:112\u2013129. https:\/\/doi.org\/10.1016\/j.jtos.2016.09.005","journal-title":"Ocul Surf"},{"key":"4602_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jprot.2016.03.031","volume":"141","author":"CC Liao","year":"2016","unstructured":"Liao CC, Chou PL, Cheng CW et al (2016) Comparative analysis of novel autoantibody isotypes against citrullinated-inter-alpha-trypsin inhibitor heavy chain 3 (ITIH3)(542\u2013556) peptide in serum from Taiwanese females with rheumatoid arthritis, primary Sjogren's syndrome and secondary Sjogren's syndrome in rheumatoid arthritis. J Proteomics 141:1\u201311. https:\/\/doi.org\/10.1016\/j.jprot.2016.03.031","journal-title":"J Proteomics"},{"key":"4602_CR29","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1002\/acr.22377","volume":"66","author":"JR Curtis","year":"2014","unstructured":"Curtis JR, Chen L, Bharat A et al (2014) Linkage of a de-identified United States rheumatoid arthritis registry with administrative data to facilitate comparative effectiveness research. Arthritis Care Res (Hoboken) 66:1790\u20131798. https:\/\/doi.org\/10.1002\/acr.22377","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-020-04602-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-020-04602-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-020-04602-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,23]],"date-time":"2021-05-23T19:12:26Z","timestamp":1621797146000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-020-04602-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,24]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["4602"],"URL":"https:\/\/doi.org\/10.1007\/s00296-020-04602-8","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,24]]},"assertion":[{"value":"13 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Leslie R. Harrold is an employee of Corrona, LLC, a shareholder in Corrona, LLC and has received grant\/research support from Pfizer and consulting fees from AbbVie, Bristol Myers Squibb, and Roche. Corrona, LLC has received funds from Bristol Myers Squibb for the analyses. Ying Shan has nothing to disclose. Sabrina Rebello is an employee of Corrona, LLC. Neil Kramer owns stock in AbbVie, Amgen, Johnson & Johnson, Pfizer and Regeneron. Evo Alemao is an employee of Bristol Myers Squibb. Sean E. Connolly and Sheila Kelly have stock options\/bond holdings in, and are employees of, Bristol Myers Squibb. Joel Kremer has stock options\/bond holdings in, and is an employee of, Corrona, LLC, has received consultancy fees from AbbVie, Amgen, Bristol Myers Squibb, Genentech, Lilly, Regeneron, Sanofi, and Pfizer; grant\/research support from AbbVie, Bristol Myers Squibb, Genentech, Lilly, Novartis and Pfizer. Elliot D. Rosenstein reports serving on an advisory board and speakers bureau for Bristol Myers Squibb.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The database used in this study was the Corrona RA registry. This study was carried out in accordance with the Declaration of Helsinki. All participating investigators were required to obtain full institutional review board approval for conducting non-interventional research involving human subjects. Sponsor approval and continuing review was obtained through a central Institutional Review Board (IRB; New England Independent Review Board, NEIRB No. 120160610). For academic investigative sites that did not receive a waiver to use the central IRB, full board approval was obtained from the respective governing IRBs and documentation of approval was submitted to Corrona, LLC prior to initiating any study procedures. All registry patients were required to provide written informed consent and authorization prior to participating.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Consent to participate: All registry patients were required to provide written informed consent and authorization prior to participating. Consent for publication: Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}